BPC-157
Overview
BPC-157 is a synthetic peptide derived from a gastric protective protein sequence. Most research is preclinical.
Mechanism
Preclinical models suggest:
- Angiogenesis support
- Tendon and ligament recovery pathways
- Gut mucosal support
Human clinical data is limited.
Candidate Considerations
- Musculoskeletal strain
- Recovery optimization
Regulatory
Compounded peptide therapy is not FDA-approved. Long-term safety data is limited.
Consultation
Medical evaluation: $99
Frequently Asked Questions
Is BPC-157 FDA-approved?
BPC-157 is not FDA-approved and is considered investigational, with limited human clinical data.
Is BPC-157 legal?
It may be prescribed as a compounded peptide under physician supervision, depending on regulatory guidelines.
Who should not use BPC-157?
Due to limited safety data, individuals should only consider use after thorough medical evaluation.
Who should not use NAD+ therapy?
Individuals with certain medical conditions, or those who are pregnant or breastfeeding, should only consider NAD+ after physician evaluation.
